Signatures of mutational processes in human cancer

Cited by (1,100)

Items 201–300 of 1,100

1. Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade
   Abida, Wassim, Cheng, Michael L., Armenia, Joshua, Middha, Sumit, Autio, Karen A., Vargas, Hebert Alberto, Rathkopf, Dana, Morris, Michael J., Danila, Daniel C., Slovin, Susan F. et al. · 2019 · JAMA Oncology
2. Substantial contribution of extrinsic risk factors to cancer development
   Song Wu, Scott Powers, Wei Zhu, Yusuf Awni Hannun · 2015 · Nature
3. Genomic Evolution of Breast Cancer Metastasis and Relapse
   Lucy R. Yates, Stian Knappskog, David C. Wedge, James H. R. Farmery, Santiago González, Iñigo Martincorena, Ludmil B. Alexandrov, Peter Van Loo, Hans Kristian Haugland, Peer Kåre Lilleng et al. · 2017 · Cancer Cell
4. PARP and PARG inhibitors in cancer treatment
   Dea Slade · 2020 · Genes & Development
5. A Compendium of Mutational Signatures of Environmental Agents
   Kucab, Jill E., Zou, Xueqing, Morganella, Sandro, Joel, Madeleine, Nanda, A. Scott, Nagy, Eszter, Gomez, Celine, Degasperi, Andrea, Harris, Rebecca, Jackson, Stephen P. et al. · 2019 · Cell
6. MutationalPatterns: comprehensive genome-wide analysis of mutational processes
   Blokzijl, Francis, Janssen, Roel, van Boxtel, Ruben, Cuppen, Edwin · 2018 · Genome Medicine
7. Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma
   Zheng, Siyuan, Cherniack, Andrew D., Dewal, Ninad, Moffitt, Richard A., Danilova, Ludmila, Murray, Bradley A., Lerario, Antonio M., Else, Tobias, Knijnenburg, Theo A., Ciriello, Giovanni et al. · 2016 · Cancer Cell
8. An Evolutionarily Conserved Function of Polycomb Silences the MHC Class I Antigen Presentation Pathway and Enables Immune Evasion in Cancer
   Marian L. Burr, Christina E. Sparbier, Kah Lok Chan, Yih-Chih Chan, Ariena J. Kersbergen, Enid Y.N. Lam, Elizabeth Azidis-Yates, Dane Vassiliadis, Charles C. Bell, Omer Gilan et al. · 2019 · Cancer Cell
9. Multi-omic machine learning predictor of breast cancer therapy response
   Sammut, Stephen-John, Crispin-Ortuzar, Mireia, Chin, Suet-Feung, Provenzano, Elena, Bardwell, Helen A., Ma, Wenxin, Cope, Wei, Dariush, Ali, Dawson, Sarah-Jane, Abraham, Jean E. et al. · 2022 · Nature
10. Human glioblastoma arises from subventricular zone cells with low-level driver mutations
    Lee, Joo Ho, Lee, Jeong Eun, Kahng, Jee Ye, Kim, Se Hoon, Park, Jun Sung, Yoon, Seon Jin, Um, Ji-Yong, Kim, Woo Kyeong, Lee, June-Koo, Park, Junseong et al. · 2018 · Nature
11. Alanyl-tRNA synthetase, AARS1, is a lactate sensor and lactyltransferase that lactylates p53 and contributes to tumorigenesis
    Zhi Zong, Feng Xie, Shuai Wang, Xiaojin Wu, Zhenyu Zhang, Bing Yang, Fangfang Zhou · 2024 · Cell
12. Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure)
    Kim, J.M., Chen, D.S. · 2016 · Annals of Oncology
13. Mechanisms of Resistance to Immune Checkpoint Blockade: Why Does Checkpoint Inhibitor Immunotherapy Not Work for All Patients?
    Charlene Marie Fares, Eliezer M. Van Allen, Charles G. Drake, James Patrick Allison, Siwen Hu‐Lieskovan · 2019 · American Society of Clinical Oncology Educational Book
14. Clear cell renal cell carcinoma ontogeny and mechanisms of lethality
    Eric W. Jonasch, Cheryl Lyn Walker, W. Kimryn Rathmell · 2020 · Nature Reviews Nephrology
15. Somatic Mutations and Clonal Hematopoiesis in Aplastic Anemia
    Yoshizato, Tetsuichi, Dumitriu, Bogdan, Hosokawa, Kohei, Makishima, Hideki, Yoshida, Kenichi, Townsley, Danielle, Sato-Otsubo, Aiko, Sato, Yusuke, Liu, Delong, Suzuki, Hiromichi et al. · 2015 · New England Journal of Medicine
16. Clinical lessons learned from the first leg of the CAR T cell journey
    Majzner, Robbie G., Mackall, Crystal L. · 2019 · Nature Medicine
17. Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial
    Joaquı́n Mateo, Núria Porta, Diletta Bianchini, Ursula McGovern, Tony Elliott, Robert J. Jones, Isabel Syndikus, Christy Ralph, Suneil Jain, Mohini Anna Varughese et al. · 2019 · The Lancet Oncology
18. Timing, rates and spectra of human germline mutation
    Raheleh Rahbari, Arthur Wüster, Sarah Lindsay, Robert J. Hardwick, Ludmil B. Alexandrov, Saeed H. Al Turki, Anna F. Dominiczak, Andrew D. Morris, David John Porteous, Blair H. Smith et al. · 2015 · Nature Genetics
19. Comprehensive Transcriptional Analysis of Early-Stage Urothelial Carcinoma
    Jakob Hedegaard, Philippe Lamy, Iver Nordentoft, Ferran Algaba B, S. Høyer, Benedicte Parm Ulhøi, Søren Vang, Thomas Reinert, Gregers Gautier Hermann, Karin Mogensen et al. · 2016 · Cancer Cell
20. Bladder Cancer, Version 1.2026, NCCN Clinical Practice Guidelines In Oncology
    Thomas W. Flaig, Philippe E. Spiess, Michael Abern, Rick Bangs, Rick Bangs, Jovan Begovic, Jason Brown, Mark K. Buyyounouski, Kevin Chan, Paul J. Chang et al. · 2020 · Journal of the National Comprehensive Cancer Network
21. Age-related remodelling of oesophageal epithelia by mutated cancer drivers
    Yokoyama, Akira, Kakiuchi, Nobuyuki, Yoshizato, Tetsuichi, Nannya, Yasuhito, Suzuki, Hiromichi, Takeuchi, Yasuhide, Shiozawa, Yusuke, Sato, Yusuke, Aoki, Kosuke, Kim, Soo Ki et al. · 2019 · Nature
22. The emerging clinical relevance of genomics in cancer medicine
    Michael F. Berger, Elaine R. Mardis · 2018 · Nature Reviews Clinical Oncology
23. New Horizons for Precision Medicine in Biliary Tract Cancers
    Juan W. Valle, Ángela Lamarca, Lipika Goyal, Jorge Barriuso, Andrew Xiuxuan Zhu · 2017 · Cancer Discovery
24. Tracking tumour evolution in glioma through liquid biopsies of cerebrospinal fluid
    Alexandra Michelle Miller, Ronak H. Shah, Elena I. Pentsova, Maryam Pourmaleki, Samuel R. Briggs, Natalie M. DiStefano, Youyun Zheng, Anna Skakodub, Smrutiben A. Mehta, Carl Campos et al. · 2019 · Nature
25. Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
    Olivier Alain Michielin, Alexander C. J. van Akkooi, Paolo A. Ascierto, Reinhard Dummer, Ulrich Keilholz · 2019 · Annals of Oncology
26. Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer
    Kyle C. Strickland, Brooke E. Howitt, Sachet Ashok Shukla, Scott J. Rodig, Lauren L. Ritterhouse, Joyce F. Liu, Judy Ellen Garber, Dipanjan Chowdhury, Catherine J. Wu, Alan D. D’Andrea et al. · 2016 · Oncotarget
27. Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors
    Miao, Diana, Margolis, Claire A., Vokes, Natalie I., Liu, David, Taylor-Weiner, Amaro, Wankowicz, Stephanie M., Adeegbe, Dennis, Keliher, Daniel, Schilling, Bastian, Tracy, Adam et al. · 2018 · Nature Genetics
28. Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer
    Alicia J. Latham, Preethi Srinivasan, Yelena M. Kemel, Jinru Shia, Chaitanya Bandlamudi, Diana L. Mandelker, Sumit Middha, Jaclyn Frances Hechtman, Ahmet Zehir, Marianne E. Dubard-Gault et al. · 2018 · Journal of Clinical Oncology
29. Realizing the promise of cancer predisposition genes
    Nazneen Rahman · 2014 · Nature
30. Melanoma
    Dirk Schadendorf, David E. Fisher, Claus Garbe, Jeffrey E. Gershenwald, Jean‐Jacques Grob, Allan C. Halpern, Meenhard Herlyn, Michael Armando Marchetti, Grant A. McArthur, Antoni Ribas et al. · 2015 · Nature Reviews Disease Primers
31. Comparative Molecular Analysis of Gastrointestinal Adenocarcinomas
    Yang Liu, Nilay S. Sethi, Toshinori Hinoue, Barbara Schneider, Andrew D. Cherniack, Francisco Sánchez-Vega, José Antonio Seoane, Farshad Farshidfar, Reanne Bowlby, Mirazul Islam et al. · 2018 · Cancer Cell
32. Tumour heterogeneity and metastasis at single-cell resolution
    Lawson, Devon A., Kessenbrock, Kai, Davis, Ryan T., Pervolarakis, Nicholas, Werb, Zena · 2018 · Nature Cell Biology
33. A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers
    Ashton C. Berger, Anil Korkut, Rupa S. Kanchi, Apurva M. Hegde, W. Frank Lenoir, Wenbin Liu, Yuexin Liu, Huihui Fan, Hui Shen, Visweswaran Ravikumar et al. · 2018 · Cancer Cell
34. The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies
    Florent Petitprez, Maxime Meylan, Aurélien de Reyniès, Catherine Sautès‐Fridman, Wolf H. Fridman · 2020 · Frontiers in Immunology
35. Combination Immunotherapy with CAR T Cells and Checkpoint Blockade for the Treatment of Solid Tumors
    Grosser, Rachel, Cherkassky, Leonid, Chintala, Navin, Adusumilli, Prasad S. · 2019 · Cancer Cell
36. Development of immuno-oncology drugs — from CTLA4 to PD1 to the next generations
    Hoos, Axel · 2016 · Nature Reviews Drug Discovery
37. Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer
    Yi-Mi Wu, Marcin P. Cieslik, Robert J. Lonigro, Pankaj Vats, Melissa Andrea Reimers, Xuhong Cao, Ning Yu, Lisha Wang, Lakshmi Priya Kunju, Navonil De Sarkar et al. · 2018 · Cell
38. Advancements in Next-Generation Sequencing
    Shawn Levy, R Myers · 2016 · Annual Review of Genomics and Human Genetics
39. Gastric adenocarcinoma
    Ajani, Jaffer A., Lee, Jeeyun, Sano, Takeshi, Janjigian, Yelena Y., Fan, Daiming, Song, Shumei · 2017 · Nature Reviews Disease Primers
40. Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies
    Arce Vargas, Frederick, Furness, Andrew J.S., Litchfield, Kevin, Joshi, Kroopa, Rosenthal, Rachel, Ghorani, Ehsan, Solomon, Isabelle, Lesko, Marta H., Ruef, Nora, Roddie, Claire et al. · 2018 · Cancer Cell
41. Genomic hallmarks of localized, non-indolent prostate cancer
    Michael E. Fraser, Veronica Y. Sabelnykova, Takafumi N. Yamaguchi, Lawrence E. Heisler, Julie M. Livingstone, Vincent Huang, Yu-Jia Shiah, Fouad Yousif, Xihui Lin, Andre P. Masella et al. · 2017 · Nature
42. Therapeutic opportunities within the DNA damage response
    Pearl, Laurence H., Schierz, Amanda C., Ward, Simon E., Al-Lazikani, Bissan, Pearl, Frances M. G. · 2015 · Nature Reviews Cancer
43. Avelumab, an Anti–Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study
    Apolo, Andrea B., Infante, Jeffrey R., Balmanoukian, Ani, Patel, Manish R., Wang, Ding, Kelly, Karen, Mega, Anthony E., Britten, Carolyn D., Ravaud, Alain, Mita, Alain C. et al. · 2017 · Journal of Clinical Oncology
44. Advances in molecular classification and precision oncology in hepatocellular carcinoma
    Sandra Rebouissou, Jean‐Charles Nault · 2020 · Journal of Hepatology
45. Bladder cancer
    Lars Dyrskjøt, Donna Elizabeth Hansel, Jason Alexander Efstathiou, Margaret A. Knowles, Matthew D. Galsky, Jeremy Yuen‐Chun Teoh, Dan Theodorescu · 2023 · Nature Reviews Disease Primers
46. Cancer Neoantigens
    Ton N. Schumacher, Wouter Scheper, Pia Kvistborg · 2018 · Annual Review of Immunology
47. Resistance to PD1/PDL1 checkpoint inhibition
    Jake S. O’Donnell, Georgina Venetia Long, Richard A. Scolyer, Michele W.L. Teng, Mark John Smyth · 2016 · Cancer Treatment Reviews
48. Multidimensional communication in the microenvirons of glioblastoma
    Marike L. D. Broekman, Sybren L. N. Maas, Erik R. Abels, Thorsten R. Mempel, Anna M. Krichevsky, Xandra O. Breakefield · 2018 · Nature Reviews Neurology
49. The Diversity of Gut Microbiome is Associated With Favorable Responses to Anti–Programmed Death 1 Immunotherapy in Chinese Patients With NSCLC
    Jin, Yueping, Dong, Hui, Xia, Liliang, Yang, Yi, Zhu, Yongqiang, Shen, Yan, Zheng, Huajun, Yao, Chengcheng, Wang, Ying, Lu, Shun · 2019 · Journal of Thoracic Oncology
50. The Genomic Landscape of Pediatric Ewing Sarcoma
    Brian D. Crompton, Chip Stewart, Amaro N Taylor-Weiner, Gabriela Alexe, Kyle C. Kurek, Monica L. Calicchio, Adam Kieżun, Scott L. Carter, Sachet Ashok Shukla, Swapnil S. Mehta et al. · 2014 · Cancer Discovery
51. A decade of checkpoint blockade immunotherapy in melanoma: understanding the molecular basis for immune sensitivity and resistance
    Alexander Chan Chi Huang, Roberta Zappasodi · 2022 · Nature Immunology
52. High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune checkpoint inhibitors
    Maleki Vareki, Saman · 2018 · Journal for ImmunoTherapy of Cancer
53. Single-Cell Analysis of Human Pancreas Reveals Transcriptional Signatures of Aging and Somatic Mutation Patterns
    Enge, Martin, Arda, H. Efsun, Mignardi, Marco, Beausang, John, Bottino, Rita, Kim, Seung K., Quake, Stephen R. · 2017 · Cell
54. γδ T cells in cancer
    Silva-Santos, Bruno, Serre, Karine, Norell, Håkan · 2015 · Nature reviews. Immunology
55. Overcoming therapy resistance in EGFR-mutant lung cancer
    Passaro, Antonio, Jänne, Pasi A., Mok, Tony, Peters, Solange · 2021 · Nature Cancer
56. Parental influence on human germline de novo mutations in 1,548 trios from Iceland
    Jónsson, Hákon, Sulem, Patrick, Kehr, Birte, Kristmundsdottir, Snaedis, Zink, Florian, Hjartarson, Eirikur, Hardarson, Marteinn T., Hjorleifsson, Kristjan E., Eggertsson, Hannes P., Gudjonsson, Sigurjon Axel et al. · 2017 · Nature
57. A causal mechanism for childhood acute lymphoblastic leukaemia
    Melvyn F. Greaves · 2018 · Nature reviews. Cancer
58. Advances in cancer immunotherapy 2019 – latest trends
    Stephan Krüger, Matthias Ilmer, Sebastian Kobold, Bruno Loureiro Cadilha, Stefan Endres, Steffen Ormanns, Gesa Schuebbe, Bernhard Willibald Renz, Jan Goesta D’Haese, Hans Schlößer et al. · 2019 · Journal of Experimental & Clinical Cancer Research
59. Longitudinal molecular trajectories of diffuse glioma in adults
    Floris P Barthel, Kevin C. Johnson, Frederick S. Varn, Anzhela D. Moskalik, Georgette Tanner, Emre Kocakavuk, Kevin J. Anderson, Olajide Abiola, Kenneth Aldape, Kristin D. Alfaro-Munoz et al. · 2019 · Nature
60. Navigating CAR-T cells through the solid-tumour microenvironment
    Andrew J. Hou, Laurence C. Chen, Yvonne Y. Chen · 2021 · Nature Reviews Drug Discovery
61. Cell-of-origin chromatin organization shapes the mutational landscape of cancer
    Polak, Paz, Karlić, Rosa, Koren, Amnon, Thurman, Robert, Sandstrom, Richard, Lawrence, Michael S., Reynolds, Alex, Rynes, Eric, Vlahoviček, Kristian, Stamatoyannopoulos, John A. et al. · 2015 · Nature
62. Mutational processes shape the landscape of TP53 mutations in human cancer
    Giacomelli, Andrew O., Yang, Xiaoping, Lintner, Robert E., McFarland, James M., Duby, Marc, Kim, Jaegil, Howard, Thomas P., Takeda, David Y., Ly, Seav Huong, Kim, Eejung et al. · 2018 · Nature Genetics
63. Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors
    Kimberley M. Heinhuis, Willeke Ros, Marleen Kok, Neeltje Steeghs, Jos H. Beijnen, Jan H.M. Schellens · 2019 · Annals of Oncology
64. PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers
    Mark M. Yarchoan, Lee A. Albacker, Alexander C. Hopkins, Meagan Montesion, Karthikeyan Murugesan, Teena Vithayathil, Neeha Zaidi, Nilofer Saba Azad, Daniel A. Laheru, Garrett Michael Frampton et al. · 2019 · JCI Insight
65. Identification of neoantigens for individualized therapeutic cancer vaccines
    Franziska Lang, Barbara Schrörs, Martin Löwer, Özlem Türeci, Uğur Şahin · 2022 · Nature Reviews Drug Discovery
66. Genomic complexity of multiple myeloma and its clinical implications
    Salomon Manier, Karma Ziad Salem, Jihye Park, Dan Avi Landau, Gad A. Getz, Irene M. Ghobrial · 2016 · Nature Reviews Clinical Oncology
67. Translational Implications of Tumor Heterogeneity
    Mariam Jamal‐Hanjani, Sergio A. Quezada, James Larkin, Charles Swanton · 2015 · Clinical Cancer Research
68. Intra-tumour diversification in colorectal cancer at the single-cell level
    Sophie F. Roerink, Nobuo Sasaki, Henry Lee-Six, Matthew D. Young, Ludmil B. Alexandrov, Sam Behjati, Thomas J. Mitchell, Sebastian Großmann, Howard W. Lightfoot, David A. Egan et al. · 2018 · Nature
69. Pheochromocytoma and paraganglioma pathogenesis: learning from genetic heterogeneity
    Dahia, Patricia L. M. · 2014 · Nature Reviews Cancer
70. Prospective Genomic Profiling of Prostate Cancer Across Disease States Reveals Germline and Somatic Alterations That May Affect Clinical Decision Making
    Abida, Wassim, Armenia, Joshua, Gopalan, Anuradha, Brennan, Ryan, Walsh, Michael, Barron, David, Danila, Daniel, Rathkopf, Dana, Morris, Michael, Slovin, Susan et al. · 2017 · JCO Precision Oncology
71. Genetic Analysis of 779 Advanced Differentiated and Anaplastic Thyroid Cancers
    Nikita V. Pozdeyev, Laurie M. Gay, Ethan S. Sokol, Ryan James Hartmaier, Kelsi E. Deaver, Stephanie Davis, Jena D. French, Pierre Vanden Borre, Daniel V. LaBarbera, Aik Choon Tan et al. · 2018 · Clinical Cancer Research
72. Cancer Screening Recommendations for Individuals with Li-Fraumeni Syndrome
    Kratz, Christian P., Achatz, Maria Isabel, Brugières, Laurence, Frebourg, Thierry, Garber, Judy E., Greer, Mary-Louise C., Hansford, Jordan R., Janeway, Katherine A., Kohlmann, Wendy K., McGee, Rose et al. · 2017 · Clinical Cancer Research
73. Characterizing genetic intra-tumor heterogeneity across 2,658 human cancer genomes
    Dentro, Stefan C., Leshchiner, Ignaty, Haase, Kerstin, Tarabichi, Maxime, Wintersinger, Jeff, Deshwar, Amit G., Yu, Kaixian, Rubanova, Yulia, Macintyre, Geoff, Demeulemeester, Jonas et al. · 2021 · Cell
74. A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer
    Polak, Paz, Kim, Jaegil, Braunstein, Lior Z, Karlic, Rosa, Haradhavala, Nicholas J, Tiao, Grace, Rosebrock, Daniel, Livitz, Dimitri, Kübler, Kirsten, Mouw, Kent W et al. · 2017 · Nature Genetics
75. A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns
    Notta, Faiyaz, Chan-Seng-Yue, Michelle, Lemire, Mathieu, Li, Yilong, Wilson, Gavin W., Connor, Ashton A., Denroche, Robert E., Liang, Sheng-Ben, Brown, Andrew M. K., Kim, Jaeseung C. et al. · 2016 · Nature
76. Genetics and biology of pancreatic ductal adenocarcinoma
    Ying, Haoqiang, Dey, Prasenjit, Yao, Wantong, Kimmelman, Alec C., Draetta, Giulio F., Maitra, Anirban, DePinho, Ronald A. · 2016 · Genes & Development
77. Relationships Between Immune Landscapes, Genetic Subtypes and Responses to Immunotherapy in Colorectal Cancer
    Emilie Picard, Chris P. Verschoor, W Kitonyi Grace, Graham Pawelec · 2020 · Frontiers in Immunology
78. Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies
    Roberta Zappasodi, Taha Merghoub, Jedd D. Wolchok · 2018 · Cancer Cell
79. APOBECs and virus restriction
    Harris, Reuben S., Dudley, Jaquelin P. · 2015 · Virology
80. Chemosensitive Relapse in Small Cell Lung Cancer Proceeds through an EZH2-SLFN11 Axis
    Eric E. Gardner, Benjamin H. Lok, Valentina E. Schneeberger, Patrice Desmeules, Linde A. Miles, Paige K. Arnold, Ai Ni, Inna Khodos, Elisa de Stanchina, Thuyen N. Nguyen et al. · 2017 · Cancer Cell
81. Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial
    Gregory Lawrence Beatty, Mark H. O’Hara, Simon Francis Lacey, Drew A. Torigian, Farzana Nazimuddin, Fang Chen, Irina M. Kulikovskaya, Michael C. Soulen, Maureen McGarvey, Anne Marie Nelson et al. · 2018 · Gastroenterology
82. MTH1 inhibition eradicates cancer by preventing sanitation of the dNTP pool
    Helge Gad, Tobias Koolmeister, Ann‐Sofie Jemth, Saeed Eshtad, Sylvain A. Jacques, Cecilia E. Ström, Linda M. Svensson, Niklas Schultz, Thomas Lundbäck, Berglind Osk Einarsdottir et al. · 2014 · Nature
83. Landscape of somatic mutations and clonal evolution in mantle cell lymphoma
    Sı́lvia Beà, Rafael Valdés‐Mas, Alba Navarro, Itziar Salaverría, David Martin‐García, Pedro Jares, Eva Giné, Magda Pinyol, Cristina Royo, Ferran Nadeu et al. · 2013 · Proceedings of the National Academy of Sciences
84. The Need for Multi-Omics Biomarker Signatures in Precision Medicine
    Michael Olivier, Reto Asmis, Gregory A. Hawkins, Timothy D. Howard, Laura A. Cox · 2019 · International Journal of Molecular Sciences
85. Timing the Landmark Events in the Evolution of Clear Cell Renal Cell Cancer: TRACERx Renal
    Thomas J. Mitchell, Samra Turajlic, Andrew Rowan, David L. Nicol, James H. R. Farmery, Tim O’Brien, Iñigo Martincorena, Patrick S. Tarpey, Nicos Angelopoulos, Lucy R. Yates et al. · 2018 · Cell
86. Recurrent gain-of-function mutations of RHOA in diffuse-type gastric carcinoma
    Miwako Kakiuchi, Takashi Nishizawa, Hiroki Ueda, Kengo Gotoh, Atsushi Tanaka, Akimasa Hayashi, Shogo Yamamoto, Kenji Tatsuno, Hiroto Katoh, Yoshiaki Watanabe et al. · 2014 · Nature Genetics
87. The mutational landscape of normal human endometrial epithelium
    Moore, Luiza, Leongamornlert, Daniel, Coorens, Tim H. H., Sanders, Mathijs A., Ellis, Peter, Dentro, Stefan C., Dawson, Kevin J., Butler, Tim, Rahbari, Raheleh, Mitchell, Thomas J. et al. · 2020 · Nature
88. Anti-PD-1 Antibody SHR-1210 Combined with Apatinib for Advanced Hepatocellular Carcinoma, Gastric, or Esophagogastric Junction Cancer: An Open-label, Dose Escalation and Expansion Study
    Xu, Jianming, Zhang, Yun, Jia, Ru, Yue, Chunyan, Chang, Lianpeng, Liu, Rongrui, Zhang, Gairong, Zhao, Chuanhua, Zhang, Yaoyue, Chen, Chunxia et al. · 2019 · Clinical Cancer Research
89. Proteomics reveals NNMT as a master metabolic regulator of cancer-associated fibroblasts
    Mark A. Eckert, Fabian Coscia, Agnieszka Chryplewicz, Jae Won Chang, Kyle M. Hernandez, Shawn Pan, Samantha M. Tienda, Dominik A. Nahotko, Gang Li, Ivana Blaženović et al. · 2019 · Nature
90. Genetics and Molecular Pathogenesis of Gastric Adenocarcinoma
    Patrick B. O. Tan, Khay Guan Yeoh · 2015 · Gastroenterology
91. Mutational signatures: the patterns of somatic mutations hidden in cancer genomes
    Alexandrov, Ludmil B, Stratton, Michael R · 2014 · Current Opinion in Genetics & Development
92. Unravelling the biology of SCLC: implications for therapy
    Joshua K. Sabari, Benjamin H. Lok, James H. Laird, John Thomas Poirier, Charles M. Rudin · 2017 · Nature Reviews Clinical Oncology
93. Signatures of copy number alterations in human cancer
    Christopher D. Steele, Ammal Abbasi, S. M. Ashiqul Islam, Amy L. Bowes, Azhar Khandekar, Kerstin Haase, Shadi Hames-Fathi, Dolapo Ajayi, Annelien Verfaillie, Pawan Dhami et al. · 2022 · Nature
94. Genomic analysis identifies new drivers and progression pathways in skin basal cell carcinoma
    Ximena Bonilla, Laurent Parmentier, Bryan King, Fedor Bezrukov, Gürkan Kaya, Vincent Zoete, Vladimir B. Seplyarskiy, Hayley J. Sharpe, Thomas McKee, Audrey Letourneau et al. · 2016 · Nature Genetics
95. Proteogenomic Characterization of Endometrial Carcinoma
    Dou, Yongchao, Kawaler, Emily A., Cui Zhou, Daniel, Gritsenko, Marina A., Huang, Chen, Blumenberg, Lili, Karpova, Alla, Petyuk, Vladislav A., Savage, Sara R., Satpathy, Shankha et al. · 2020 · Cell
96. Oncotator: Cancer Variant Annotation Tool
    Alex H. Ramos, Lee Lichtenstein, Manaswi Gupta, Michael S. Lawrence, Trevor J. Pugh, Gordon Saksena, Matthew M. Meyerson, Gad A. Getz · 2015 · Human Mutation
97. ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer
    Rowan E. Miller, Alexandra F. Leary, Clare L. Scott, Violeta Serra, Christopher J. Lord, David D.L. Bowtell, David Kuang-Fu Chang, Dale W. Garsed, Jos Jonkers, Jonathan Andrew Ledermann et al. · 2020 · Annals of Oncology
98. Genome-wide analysis of noncoding regulatory mutations in cancer
    Weinhold, Nils, Jacobsen, Anders, Schultz, Nikolaus, Sander, Chris, Lee, William · 2014 · Nature Genetics
99. Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer
    Zhu, Gongmin, Pei, Lijiao, Xia, Hongwei, Tang, Qiulin, Bi, Feng · 2021 · Molecular Cancer
100. Origins and functional consequences of somatic mitochondrial DNA mutations in human cancer
     Ju, Young Seok, Alexandrov, Ludmil B, Gerstung, Moritz, Martincorena, Inigo, Nik-Zainal, Serena, Ramakrishna, Manasa, Davies, Helen R, Papaemmanuil, Elli, Gundem, Gunes, Shlien, Adam et al. · 2014 · eLife